Patent · US Expired

Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto

US5480968A · kind A · utility

174Cited by
1References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 10, 1992
Grant dateJan 2, 1996
Priority date
Expiry dateNov 10, 2012

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2500/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A DNA fragment distinct from the epidermal growth factor receptor (EGFR) and erbB-2 genes was detected by reduced stringency hybridization of v-erbB to normal genomic human DNA. Characterization of the cloned DNA fragment mapped the region of v-erbB homology to three exons with closest homology of 64% and 67% to a contiguous region within the tyrosine kinase domains of the EGFR and erbB-2 proteins, respectively. cDNA cloning revealed a predicted 148 kd transmembrane polypeptide with structural features identifying it as a member of the erbB family, prompting designation of the new gene as erbB-3. It was mapped to human chromosome 12 ql 11-13 and was shown to be expressed as a 6.2 kb transcript in a variety of normal tissues of epithelial origin. Markedly elevated erbB-3 mRNA levels were demonstrated in certain human mammary tumor cell lines. These findings indicate that increased erbB-3 expression, as in the case of EGFR and erbB-2, plays a role in some human malignancies. Using erbB-3 specific antibodies (polyclonal or monoclonal), the erbB-3 protein was identified as a 180 kDa glycoprotein, gp180.sup.EGFR/erbB-3. The intrinsic catalytic function of gp180.sup.erbB-3 was uncovered …

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.